Come and join us at this octane annual summer networking event and learn from a world-class expert on cutting-edge technologies in healthcare 3D printing and bioprinting industry.
33-41 Farnsworth Street
Boston, MA 02210
6:30-7:00 PM Registration/Networking
7:00-7:15 PM Sponsor/3DHEALS/Boston Community Manager Intro
7:15-7:25 PM Scott Rader (GE Healthcare) From hype to hope: translating 3D printed promises to healthcare realities– A view from the trenches
7:25-7: 30 PM Q&A
7:30-7: 40 PM Kimberly Homan Kidney Tissue Regeneration and Bioprinting
7:40-7:45 PM Q&A
7:45-7:55 PM Richard McFarland, M.D., Ph.D. (ARMI, USA) Bioprinting: The Panacea or yet another Pandora’s Box for Regenerative Medicine?
7:55-8:00 PM Q&A
8:00-8:10 PM Albert Woo, M.D. 3D Printing for Reconstruction Surgery
8:10-8:15 PM Q&A
8:15-8:45 PM Panel Q&A
8:45-9:30 PM Networking and wrap-up
(After event location will be announced to continue the conversations.)
Kimberly Homan just moved from being a Research Associate at the Wyss Institute for Biologically Inspired Engineering at Harvard to a position in a stealth-mode startup company. She started her scientific career at the University of Arizona where she earned a chemical engineering degree. She then took a break from science and was commissioned a logistics officer in the United States Marine Corps where she served for 6 years. After her service, she attended the University of Texas at Austin where she earned a Ph.D. in biomedical engineering. While in Austin, Texas she started a company based on the biomedical imaging contrast agents she developed in her graduate work. Her company, NanoHybrids Inc, is still based in Austin and has brought several lines of unique gold nanoparticles to market. Kimberly then applied her biomedical engineering expertise to tissue engineering and worked for the last 6 years to use 3D bioprinting to create functional living tissues. In the laboratory of Jennifer Lewis at Harvard University in Wyss and in collaboration with Annie Moisan at Roche, she built kidney tissue on perfusable chips that can be used for drug screening, mechanistic safety, and ultimately, regenerative medicine.
Richard McFarland, Ph.D., MD joins ARMI as its Chief Regulatory Officer effective May 1, 2017. Dr. McFarland comes to ARMI from the Food and Drug Administration’s Center for Biologics Evaluation and Research (FDA/CBER) where his career spanning 16 years involved review over an extensive range of products and policy development in numerous areas both inside FDA, across the federal government, and internationally. He spent more than a decade as Associate Director of Policy for FDA/CBER’s Office of Tissues and Advanced Therapies and its predecessor office, the Office of Cellular, Tissue and Gene Therapies. In this position, he was heavily involved in policy development for tissue engineering, regenerative medicine, and alternatives to animal use in regulatory decision making. In addition to the development of risk-based regulatory oversight paradigms within FDA, his interests included broader efforts to create an interlocking network of interagency efforts to foster the growth of basic and translational science to support the maturation of the overlapping fields of tissue engineering and regenerative medicine from primarily discovery science toward a stage of commercial development.
His position at ARMI will allow him to apply the knowledge and experiences gained by over the last decade and half in the field to ARMI’s efforts to establish an industrial common, in the form of a Manufacturing Innovation Institute within the Manufacturing USA network, with the aims to coalesce the field and provide a route for nascent product concepts to reach the marketplace. Bringing these products to the market will benefit critical U.S. public health needs and will provide the economic drivers needed to create new highly-skilled jobs.
Dr. McFarland, Ph.D., M. D. received his B.S., Ph.D., and M.D. from the University of North Carolina at Chapel Hill, and completed his anatomic/clinical pathology residency and immunopathology fellowship training at UT Southwestern in Dallas. Immediately prior to joining the FDA, he was on the faculty of the Pathology Department of the University of Texas Southwestern in Dallas. In addition to FDA policy documents he has co-authored over 25 articles in peer-reviewed articles journals including Nature, the Proceedings of the National Academy of Science (PNAS), and Blood.
Bioprinting: The Panacea or yet another Pandora’s Box for Regenerative Medicine?
Scott Rader is an accomplished medical device executive with a consistent record of achievement spanning multiple areas of clinical product focus. Broad functional expertise in product development, team building, entrepreneurship, marketing and business development. A decisive entrepreneur with practical experience bringing products to market, building IP portfolios (holds fourteen patents), raising venture capital and championing product development.
Talk Title: From hype to hope: translating 3D printed promises to healthcare realities– A view from the trenches
Dr. Albert Woo, FACS is a board-certified plastic and reconstructive surgeon who specializes in the treatment of cleft and craniofacial anomalies. This work has led to a particular interest in three-dimensional imaging and printing of complex surgical models. He is an Associate Professor of Surgery, Pediatrics, and Neurosurgery at The Warren Alpert Medical School of Brown University and serves as the Chief of the Division of Pediatric Plastic Surgery, Director of the Cleft and Craniofacial Center at Hasbro Children’s Hospital, and Director of the new Lifespan 3D Printing Laboratory.
Besides medical 3D printing, Dr. Woo’s clinical interests include the surgical treatment of patients with craniosynostosis, complex and syndromic craniofacial abnormalities, and cleft deformities. In particular, he is internationally recognized as an expert in cleft palate repair, after having developed a new surgical technique for this procedure. He is also a nationally recognized for his expertise in Endoscopic Craniosynostosis Surgery, with numerous papers and national presentations on the subject. With more than 60 peer-reviewed publications, numerous chapters and a book, Dr. Woo remains committed not only to clinical excellence but also to advancing research in the treatment of craniofacial anomalies.
Dr. Woo currently is a member of numerous societies including the American College of Surgeons, the American Society of Maxillofacial Surgeons, the American Cleft Palate-Craniofacial Association, the American Association of Plastic Surgeons, and the American Society of Plastic Surgeons. He is the recipient of numerous awards, including recognition by Best Doctors in America since 2011 and Castle Connolly’s Top Doctors.
3DHEALS/CMIT 2019: Entrepreneurship and Commercialization workshop during CMIT, UCLA, 2019